Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma

Drugs of Today

Volumn 50, Issue 4, 2014, Pages 291-300

  McDermott, J ^a   Jimeno, Antonio ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic lymphocytic leukemia; Ibrutinib; Mantle cell lymphoma; Tyrosine kinase inhibitor

Indexed keywords

AMPRENAVIR; APREPITANT; ATAZANAVIR; B LYMPHOCYTE RECEPTOR; BOCEPREVIR; BORTEZOMIB; CHEMOKINE; CIPROFLOXACIN; CRIZOTINIB; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOKINE; DARUNAVIR; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FOSAMPRENAVIR; IBRUTINIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDINAVIR PLUS RITONAVIR; INTEGRIN; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE; NEFAZODONE; NELFINAVIR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; SAQUINAVIR; TELAPREVIR; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITOR INTERACTION; FOOD AND DRUG ADMINISTRATION; GERIATRIC PATIENT; GRAPEFRUIT; HUMAN; IC 50; LEUKEMIA CELL; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR MICROENVIRONMENT;

CHRONIC LYMPHOCYTIC LEUKEMIA; IBRUTINIB; MANTLE CELL LYMPHOMA; TYROSINE KINASE INHIBITOR;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84899719994     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.4.2133570     Document Type: Article

References (40)

1. National Cancer Institute. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. http://seer.cancer.gov/statfacts/html/leuks.html. Accessed February 5, 2014.
2. Hallek, M., Cheson, B.D., Catovsky, D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Croup 1996 guidelines. Blood 2008, 111(12): 5446-56.
3. Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N., Pasternack, B.S. Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46(2): 219-34.
4. Binet, J.L, Auquier, A., Dighiero, G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48(1): 198-206. (Pubitemid 11064396)
5. Rossi, D., Rasi, S., Spina, V. et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013, 121(8): 1403-12.
6. Rassenti, L.Z., Jain, S., Keating, M.J. et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008, 112(5): 1923-30.
7. Smedby, K.E., Hjalgrim, H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol 2011, 21(5): 293-8.
8. Zukerberg, L.R., Yang, W.I., Arnold, A., Harris, N.L. Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. Am J Clin Pathol 1995, 103(6): 756-60.
9. Bertoni, F., Rinaldi, A., Zucca, E., Cavalli, F. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 2006, 24(1): 22-7.
10. Hoster, E., Dreyling, M., Klapper, W. et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111(2): 558-65.
11. Ghielmini, M., Zucca, E. How I treat mantle cell lymphoma. Blood 2009, 114(8): 1469-76.
12. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999, 91(10): 861-8.
13. Gribben, J.G. How I treat CLL up front. Blood 2010, 115(2): 187-97.
14. Goede, V., Fischer, K., Busch, R. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014, 370(12): 1101-10.
15. Rummel, M.J., Niederle, N., Maschmeyer, G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013, 381(9873): 1203-10.
16. Smith, M.R. Is early hematopoietic stem-cell transplantation necessary in mantle-cell lymphoma? J Clin Oncol 2014, 32(4): 265-7.
17. Bruton, O.C. Agammaglobulinemia. Pediatrics 1952, 9(6): 722-8.
18. Vetrie, D., Vorechovsky, I., Sideras, P. et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993, 361(6409): 226-33. (Pubitemid 23034471)
19. Genevier, H.C., Hinshelwood, S., Gaspar, H.B. et al. Expression of Bruton's tyrosine kinase protein within the B cell lineage. Eur J Immunol 1994, 24(12): 3100-5.
20. Smith, C.I., Baskin, B., Humire-Greiff, P. et al. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol 1994, 152(2): 557-65. (Pubitemid 24072959)
21. Petro, J.B., Rahman, S.M., Ballard, D.W., Khan, W.N. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med 2000, 191(10): 1745-54.
22. Stevenson, F.K., Caligaris-Cappio, F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004, 103(12): 4389-95. (Pubitemid 38745961)
23. Stevenson, F.K., Krysov, S., Davies, A.J., Steele, A.J., Packham, G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118(16): 4313-20.
24. Pan, Z., Scheerens, H., Li, S.J. et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007, 2(1): 58-61.
25. Honigberg, L.A., Smith, A.M., Sirisawad, M. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010, 107(29): 13075-80.
26. Herman, S.E., Gordon, A.L., Hertlein, E. et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117(23): 6287-96.
27. de Rooij, M.F., Kuil, A., Geest, C.R. et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119(11): 2590-4.
28. Ponader, S., Chen, S.S., Buggy, J.J. et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119(5): 1182-9.
29. Meads, M.B., Hazlehurst, L.A., Dalton, W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14(9): 2519-26.
30. Westhoff, M.A., Fulda, S. Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat 2009, 12(4-5): 127-36.
31. Woyach, J.A., Bojnik, E., Ruppert, A.S. et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 2014, 123(8): 1207-13.
32. Cinar, M., Hamedani, F., Mo, Z., Cinar, B., Amin, H.M., Alkan, S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res 2013, 37(10): 1271-7.
33. Chang, B., Francesco, M., Steggerda, S. Ibrutinib inhibits malignant cell adhesion and migration and reduces tumor burden in lymph node and bone marrow in a murine model of mantle cell dissemination and progression. Annu Meet Am Assoc Cancer Res (April 6-10, Washington, D.C.) 2013, Abst 923.
34. Advani, R.H., Buggy, J.J., Sharman, J.P. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31(1): 88-94.
35. Byrd, J.C., Furman, R.R., Coutre, S.E. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369(1): 32-42.
36. O'Brien, S., Furman, R.R., Coutre, S.E. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014, 15(1): 48-58.
37. Wang, M.L., Rule, S., Martin, P. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013, 369(6): 507-16.
38. Brown, J.R., Barrientos, J.C., Barr, P.M., et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: Final results of a phase 1b study. Annu Meet Am Soc Hematol (December 7-10, New Orleans) 2013, Abst 525.
39. Burger, J.A., Keating, M.J., Wierda, W.G., et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): New, updated results of a phase II trial in 40 patients. Annu Meet Am Soc Hematol (December 7-10, New Orleans) 2013, Abst 675.
40. Product Information: IMBRUVICA™ oral capsules, ibrutinib oral capsules. Pharmacyclics, Inc. (per manufacturer). Sunnyvale, CA, November 2013.